ECSP19085451A - Composiciones de insulina de rápida acción - Google Patents

Composiciones de insulina de rápida acción

Info

Publication number
ECSP19085451A
ECSP19085451A ECSENADI201985451A ECDI201985451A ECSP19085451A EC SP19085451 A ECSP19085451 A EC SP19085451A EC SENADI201985451 A ECSENADI201985451 A EC SENADI201985451A EC DI201985451 A ECDI201985451 A EC DI201985451A EC SP19085451 A ECSP19085451 A EC SP19085451A
Authority
EC
Ecuador
Prior art keywords
fast
acting insulin
insulin compositions
insulin
compositions
Prior art date
Application number
ECSENADI201985451A
Other languages
English (en)
Inventor
Chad Donald Paavola
Jun Zhang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP19085451A publication Critical patent/ECSP19085451A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención es una composición de insulina o análogo de insulina que tiene una acción farmacocinética más rápida que las formulaciones comerciales de productos análogos de insulina de inicio rápido.
ECSENADI201985451A 2017-06-01 2019-11-29 Composiciones de insulina de rápida acción ECSP19085451A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762513645P 2017-06-01 2017-06-01

Publications (1)

Publication Number Publication Date
ECSP19085451A true ECSP19085451A (es) 2019-12-27

Family

ID=62779004

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201985451A ECSP19085451A (es) 2017-06-01 2019-11-29 Composiciones de insulina de rápida acción

Country Status (24)

Country Link
US (1) US11207384B2 (es)
EP (1) EP3630166B1 (es)
JP (1) JP6920471B2 (es)
KR (2) KR20190140048A (es)
CN (1) CN110662551B (es)
AU (1) AU2018275545B2 (es)
CA (1) CA3065308C (es)
CL (1) CL2019003336A1 (es)
CO (1) CO2019013251A2 (es)
CR (1) CR20190522A (es)
DO (1) DOP2019000300A (es)
EA (1) EA201992351A1 (es)
EC (1) ECSP19085451A (es)
ES (1) ES2912162T3 (es)
IL (1) IL270975B2 (es)
JO (1) JOP20190277B1 (es)
MA (1) MA50496A (es)
MX (1) MX2019014195A (es)
NZ (1) NZ758298A (es)
PE (1) PE20200017A1 (es)
PH (1) PH12019502677A1 (es)
SA (1) SA519410672B1 (es)
UA (1) UA126450C2 (es)
WO (1) WO2018222787A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3170615A1 (en) * 2020-03-02 2021-09-10 Thermalin Inc. Compositions containing rapid-acting insulin analogues
AU2021356578A1 (en) * 2020-10-08 2023-05-11 Dr. Mary Morris & Associates, Llc Methods and compositions for the treatment and prevention of type 1 diabetes

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3064888D1 (en) 1979-04-30 1983-10-27 Hoechst Ag Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
WO1988006599A1 (en) 1987-02-25 1988-09-07 Novo Industri A/S Novel insulin derivatives
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
US5547942A (en) 1994-01-04 1996-08-20 Rapaport; Eliezer Method of treatment of diabetes mellitus by administration of adenosine 5'-t
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
AUPO066096A0 (en) 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
EP1044016B1 (en) 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
ES2180511T3 (es) 1999-01-26 2003-02-16 Lilly Co Eli Formulaciones monodispersas de analogos de insulina acilados hexamericos.
JP2003514014A (ja) 1999-11-15 2003-04-15 ティー ガンガル，ハナマラディ 静脈注入のためのブドウ糖およびインスリン含有液体配合物
US7084126B1 (en) 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
US20020141946A1 (en) 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
DE10351594A1 (de) * 2003-11-05 2005-06-16 Tecpharma Licensing Ag Vorrichtung für die Verabreichung eines injizierbaren Produkts
EP2106790B1 (en) 2004-03-12 2012-10-24 Biodel, Inc. Rapid acting drug delivery compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
WO2007041481A1 (en) 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
CN101754747A (zh) 2007-06-05 2010-06-23 Paka肺部医药公司 用于向肺脏递送药物的方法以及组合物
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US20120094902A1 (en) * 2009-03-27 2012-04-19 Adocia Fast-acting insulin formulation
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
US20120178675A1 (en) 2010-07-07 2012-07-12 Biodel Inc. Compositions And Methods For Modulating The Pharmacokinetics and Pharmacodynamics of Insulin
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
BR112013032265A2 (pt) 2011-06-17 2016-12-20 Halozyme Inc métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
BR112014016195A2 (pt) 2011-12-30 2020-10-27 Halozyme, Inc. variantes de polipeptídio ph20, formulações e usos das mesmas
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
US9381247B2 (en) 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
KR20150082640A (ko) 2012-11-13 2015-07-15 아도시아 치환된 음이온성 화합물을 포함하는 속효성 인슐린 제형
US20150065423A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
WO2015106269A2 (en) 2014-01-13 2015-07-16 Thermalin Diabetes, Llc Rapid action insulin formulations and pharmaceutical delivery systems
WO2015120457A1 (en) 2014-02-10 2015-08-13 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations
JO3624B1 (ar) 2014-05-08 2020-08-27 Lilly Co Eli تركيبات إنسولين سريعة المفعول
US9795678B2 (en) * 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
TW201630622A (zh) * 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
ES2972423T3 (es) 2015-07-28 2024-06-12 Lilly Co Eli Preparado farmacéutico para mejorar la absorción y la acción hipoglucemiante postprandial de la insulina
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
WO2018023060A1 (en) 2016-07-29 2018-02-01 Massachusetts, University Of Small molecule inhibitors for transcription factors
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations

Also Published As

Publication number Publication date
IL270975B2 (en) 2024-02-01
PE20200017A1 (es) 2020-01-06
AU2018275545B2 (en) 2021-02-04
CN110662551B (zh) 2023-07-18
US20200078446A1 (en) 2020-03-12
MA50496A (fr) 2020-09-09
CA3065308C (en) 2022-05-17
KR102342865B1 (ko) 2021-12-24
JOP20190277A1 (ar) 2019-11-28
DOP2019000300A (es) 2019-01-15
CN110662551A (zh) 2020-01-07
EA201992351A1 (ru) 2020-03-26
SA519410672B1 (ar) 2022-06-16
JOP20190277B1 (ar) 2023-09-17
CL2019003336A1 (es) 2020-05-15
US11207384B2 (en) 2021-12-28
IL270975A (en) 2020-01-30
JP2020522470A (ja) 2020-07-30
CR20190522A (es) 2020-01-15
KR20210106029A (ko) 2021-08-27
KR20190140048A (ko) 2019-12-18
WO2018222787A1 (en) 2018-12-06
EP3630166A1 (en) 2020-04-08
PH12019502677A1 (en) 2020-06-08
MX2019014195A (es) 2020-01-27
UA126450C2 (uk) 2022-10-05
AU2018275545A1 (en) 2019-10-31
CA3065308A1 (en) 2018-12-06
JP6920471B2 (ja) 2021-08-18
BR112019022212A2 (pt) 2020-05-12
CO2019013251A2 (es) 2020-01-17
ES2912162T3 (es) 2022-05-24
IL270975B1 (en) 2023-10-01
EP3630166B1 (en) 2022-04-06
NZ758298A (en) 2022-11-25

Similar Documents

Publication Publication Date Title
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
MX367521B (es) Composiciones de insulina de rápida acción.
CL2018000503A1 (es) Composiciones de insulina de rápida acción
MX2016009625A (es) Proteinas quimericas tipo fosfatasa alcalina.
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
BR112017006137A2 (pt) formulação que contém biotensoativo
MX2018009938A (es) Profarmacos de hormona paratiroidea (pth).
BR112017022089A2 (pt) uso de uma composição, e, método para branqueamento de dentes
BR112016028697A2 (pt) artigos que fornecem fragrâncias de longa duração
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
MX2020004782A (es) Composiciones de lagrimas artificiales.
MX385910B (es) Composiciones de fragancia que comprenden ciclohexanoato de etilo.
ECSP19085451A (es) Composiciones de insulina de rápida acción
ES1216222Y (es) Composicion que comprende cenizas de cremacion
MX2021004115A (es) Derivados de alcoxibenzaldehido y precursores de los mismos.
MX2021004581A (es) Composiciones acuosas que comprenden omega nitrooxi-1-alcanoles.
MX376853B (es) Odorante osmanthus.
AR108149A1 (es) Producto para el cuidado bucal
CL2018002949A1 (es) Composiciones para el cuidado bucal.
CO2018001431A2 (es) 2,4,7-trimetiloct-6-en-1-ol como ingrediente de fragancia
BR112018013900A2 (pt) composições de fragrância de liberação prolongada
CL2019000283S1 (es) Envase de perfume.
TH170188A (th) องค์ประกอบสำหรับการทำความสะอาดช่องปาก
AR100354A1 (es) Composiciones farmacéuticas de danirixina para el tratamiento de enfermedades infecciosas